Liftstream is an executive search recruitment company in the life sciences sector
Big-Pharma Defection Continues
In a continuation of a developing trend, two big-pharma executives left their cozy corner offices for the fast and wild biotech world. This year we have already seen a number of big names defect for the biotech world, the reasons for which were covered here. These latest appointments add further evidence to the fact that biotech has regained its form and now has pulling power.
M&A Continues to Dominate the Rare Diseases Landscape
Alexion took everyone by surprise in recent weeks by announcing a very sizable acquisition of Boston-based Synageva for $8.4bn. This was a significant deal which will only serve to strengthen valuations of rare disease biotechnology companies, which continue to be in the M&A cross-hairs of both pharmaceutical and big-biotech companies.
Pfizer and Merck collaborate for cancer immunotherapy
Authored by James Sheppard
UK Government names biotech veteran Minister for Life Sciences
Authored by James Sheppard
David Roth appointed Chief Medical Officer of Infinity
Authored by Karl Simpson
Versartis follows CFO hire with Chairman appointment
Authored by Karl Simpson
Merus Biopharmaceuticals building to future with strong pipeline
Authored by James Sheppard
immatics bags $46m for Phase III cancer vaccine
Authored by James Sheppard
Pfizer gains experimental drug from Gliknik
Authored by James Sheppard
AstraZeneca Binds to biologics for new strategy Horizon
Authored by James Sheppard